ENTITY
BeiGene

BeiGene (6160 HK)

303
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
03 Dec 2018 08:00

Junshi Biosciences IPO Preview: A Sense of Déjà Vu Without the Excitement

Shanghai Junshi Bioscience Co. Ltd. (1387344D CH) is a biopharmaceutical company which is developing a pipeline of 13 biologic drugs, including...

Logo
413 Views
Share
27 Nov 2018 05:23

EM Health Care:  Late Cycle Rotation

Emerging Market Health Care allocations sit towards the lower end of their 7-year range. Current levels are off their 2015 highs by a margin, with...

Logo
339 Views
Share
bearishWuXi AppTec
26 Nov 2018 05:52

Last Week in GER Research: WuXi App, Don Quijote, Koolearn, Asiainfo and China's Bike Sharing Bubble

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week we update on IPO WuXi AppTec Co....

Logo
429 Views
Share
bearishBabytree Group
19 Nov 2018 11:47

Last Week in GER Research: Babytree, NTT, Tongcheng, IDreamSky, Fosun, Sinochem, and Mogu

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week we highlight the latest on...

Logo
645 Views
Share
12 Nov 2018 09:54

Junshi Bioscience (君实医药) IPO: Early in Application but Behind in Key Indications (Part 1)

Shanghai Junshi Biosciences, a China-based biotechnology company listed on the NEEQ market (ticker 833330.NEEQ) with a market capitalization of USD...

Logo
473 Views
Share
x